Jpmorgan Chase & CO Clene Inc. Transaction History
Jpmorgan Chase & CO
- $1.1 Trillion
- Q1 2024
A detailed history of Jpmorgan Chase & CO transactions in Clene Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 15 shares of CLNN stock, worth $4. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15
Previous 15
-0.0%
Holding current value
$4
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding CLNN
# of Institutions
54Shares Held
7.44MCall Options Held
48.1KPut Options Held
160K-
Vanguard Group Inc Valley Forge, PA2.62MShares$864,5010.0% of portfolio
-
Geode Capital Management, LLC Boston, MA947KShares$312,3550.0% of portfolio
-
Lunt Capital Management, Inc. Holladay, UT513KShares$169,2440.11% of portfolio
-
Scoggin Management LP New York, NY500KShares$165,0000.08% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL474KShares$156,4620.0% of portfolio
About Clene Inc.
- Ticker CLNN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 63,502,000
- Market Cap $21M
- Description
- Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral scleros...